Clinical trials
Primary Liver Cancer clinical trials
Below are recruiting primary liver cancer clinical trials, each written for real people, not researchers. We’re tracking 230 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06326502RecruitingPhase 1
A study of ETN101 for advanced liver cancer
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
SeoulAges 19–65 - NCT06544083Recruiting
Blood test for early liver cancer detection
This trial is testing if a blood test can find liver cancer early. It may help people who are newly diagnosed or suspected to have liver cancer and have not started treatment yet.
Hangzhou, ZhejiangAges 18–75 - NCT06641713Recruiting
Comparing two liver cancer treatments for large tumors
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
Beijing, Beijing MunicipalityAges 18–75 - NCT06778317Recruiting
Blood test to predict liver cancer in cirrhosis patients
This trial tests if a simple blood test can help predict who with cirrhosis might develop liver cancer, so doctors can monitor and treat those patients earlier.
Vandœuvre-lès-NancyAges 18 years+ - NCT06898398Recruiting
TACE before surgery for large liver cancer
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT07166406RecruitingPhase 3
Immunotherapy with or without targeted radiation for advanced liver cancer
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
Berkeley, CaliforniaAges 18 years+ - NCT07285850RecruitingPhase 2/Phase 3
Sequential treatment for advanced liver cancer with fatty liver
This trial tests a combination of two medications, bevacizumab and atezolizumab, given one after the other to treat advanced liver cancer that cannot be surgically removed. It is specifically for people whose liver cancer is linked to a fatty liver condition (MASLD). The goal is to see if this approach helps shrink tumors or control the disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07295340Recruiting
New imaging dye test for liver cancer detection
This trial tests a special dye that targets liver cancer cells to help surgeons see tumor edges more clearly during surgery. It may help ensure all cancer is removed in one operation.
Chengdu, SichuanAges 18–80 - NCT07495215RecruitingPhase 1/Phase 2
Personalized mRNA vaccine plus immunotherapy for liver cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
Hangzhou, ZhejiangAges 18–75 - NCT07623265Recruiting
Understanding Immunotherapy Response in Liver Cancer
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
AntwerpAges 18 years+ - NCT05538091RecruitingPhase 2
Testing vismodegib plus atezolizumab for platinum-resistant ovarian cancer
This Phase 2 trial tests whether combining vismodegib with atezolizumab can slow or shrink platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It targets cancers that grow again within 6 months after platinum chemotherapy.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05876182RecruitingPhase 2
Vancomycin for primary sclerosing cholangitis
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
Monza, Monza E BrianzaAges 15–70 - NCT04919629RecruitingPhase 2
Tested treatments for recurrent ovarian cancer with fluid buildup
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
Buffalo, New YorkAges 18 years+ - NCT06860815RecruitingPhase 2
Cemiplimab with liver radiation for breast cancer that spread to the liver
This trial tests a combination of a drug called cemiplimab (an immunotherapy that helps your immune system fight cancer) and a type of targeted radiation (Y-90 SIR-Spheres) given directly to liver tumors. It is for people with breast cancer that has spread to the liver and who have already had at least one type of chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT06501482RecruitingPhase 3
FOLFIRI after liver surgery for colorectal cancer
This trial tests whether adding FOLFIRI chemotherapy after surgery for liver metastases from colorectal cancer can reduce the risk of the cancer coming back. It's for people whose liver tumors responded well to the same chemotherapy before surgery.
Paris, Île-de-France RegionAges 18 years+ - NCT02931513Recruiting
Blood marker test in newly diagnosed PBC patients
This study looks at how a specific blood marker (sCD163) changes in people newly diagnosed with primary biliary cholangitis (PBC). It’s mainly meant to see whether this marker could help predict treatment response, especially before starting UDCA.
Aarhus C, Central JutlandAges 18 years+ - NCT06638931RecruitingPhase 2
Nivolumab for rare solid tumors with high PD-L1
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
Fortaleza, CearáAges 18 years+ - NCT06504147RecruitingPhase 2
Radspherin for ovarian cancer with peritoneal spread
This trial tests a radioactive treatment called Radspherin given during surgery for advanced ovarian cancer that has spread to the lining of the abdomen. It is for people whose tumors are HR proficient (a specific genetic type) and who have already had chemotherapy before surgery.
Tampa, FloridaAges 18 years+ - NCT06252753Recruiting
Study of durvalumab for liver and bile duct cancer
This study looks at people with liver or bile duct cancer who are treated with the drug durvalumab (Imfinzi). It aims to collect information on how well the treatment works in real-world settings.
Birmingham, AlabamaAges 18–130 - NCT07193862RecruitingEarly Phase 1
Testing a tiny device to find best treatments for liver tumors
This study tests a tiny device that is placed in your liver tumor during surgery. It checks how well different chemotherapy drugs work on your specific cancer, which may help your doctor choose the best treatment for you.
Lake Success, New YorkAges 18 years+ - NCT07172282RecruitingEarly Phase 1
Immunotherapy for colorectal cancer liver metastases
This trial tests a new way to deliver immunotherapy directly into the liver for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors before surgery, and it may be an option if you've already had standard chemotherapy.
Lake Success, New YorkAges 18 years+ - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
Boston, MassachusettsAges 18 years+ - NCT06449937Recruiting
Local liver treatment for colorectal cancer that has spread
This trial tests whether treating liver tumors with surgery or ablation can help people whose colorectal cancer has spread to the liver and other organs. It may be an option if you've had only 1 or 2 types of chemotherapy and your non-liver metastases are stable.
Chuzhou, AnhuiAges 18–80 - NCT06476184RecruitingPhase 3
Adjusted chemo dosing for hard-to-treat ovarian cancer
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
AngersAges 18 years+
Hear when a new Primary Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary liver cancer?
- Yes. Clin2 currently lists 230 recruiting primary liver cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary liver cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary liver cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.